Trenbolone is as strong of an androgen as it is an anabolic, where its androgenic strength is also that of five times the strength of Testosterone. With an androgenic rating of 500, it is commonly known that Trenbolone can and does exhibit increased feelings of irritability and aggression in most users. This side effect is very dose-dependent, with more pronounced aggression seen in higher (and often unnecessary) Trenbolone doses. Various individuals will also not experience tis side effect at all as a result of their individual response. Users who are known to have short temper and anger-control issues prior to Trenbolone use should exercise extreme caution, as the use of Trenbolone can and will without a doubt cause an amplification of these traits. Such individuals should avoid Trenbolone use as a responsible decision. As a general overall rule, any and all Tren users should always exercise caution and ensure that a proper stable psychological state is always maintained, and that the user be constantly aware of their actions at all times. Appropriate discipline is of the utmost importance when utilizing any anabolic steroid, especially Trenbolone (and special considerations must be taken at higher doses). It must be made crystal clear to the reader that the use of any type of drug is absolutely no reason for any individual to absolve themselves of all personal responsibility, and shift the blame onto the drug in question (in this case, Trenbolone) when the user commits a regrettable action. Remember this at all times!
In a study of 1,685 patients treated with CPA, elevated liver enzymes were seen in 10% of patients at a dosage of 50 mg/day and in 20% of patients at a dosage of greater than 100 mg/day.  A study of 2,506 patients given 18–136 mg/day for less than 48 months per patient reported a rate of %.   In a trial of 89 prostate cancer patients who received high-dose CPA for 4 years, there were elevated liver enzymes in % of the patients.  Yet another study of 105 patients found a hepatotoxicity rate of %, with serious hepatic injury occurring in %.  In 2002, it was reported that there were 18 case reports of CPA-associated hepatitis in the medical literature, with 6 of the cases resulting in death.  In addition, a review article cited a report of 96 instances of hepatotoxicity that were attributed to CPA, and 33 of these instances resulted in death.  Moreover, a 2014 review found that 15 cases specifically of CPA-induced fulminant (sudden-onset and severe) liver failure had been reported to date, with only one of these cases not resulting in death.  As such, the prognosis of CPA-induced liver failure is death. 
In 16-day studies, all five male and five female rats and mice dosed with 2,000 mg/kg benzyl alcohol died. Two of five male and 3/5 female rats and 1/5 male and 2/5 female mice dosed with 1,000 mg/kg died. Rats and mice of each sex in the two highest dose groups were lethargic after dosing. Other toxic responses to benzyl alcohol in these dose groups included blood around the mouth and nose, subcutaneous hemorrhages, and blood in the urinary and gastrointestinal tracts of rats and blood in the urinary bladder of mice. Animals administered lower doses of benzyl alcohol (125, 250, or 500 mg/kg) had no compound-related histologic lesions.